Newfeed

SHANGHAI, Dec. 12, 2023  /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the NDA for new indication of HANSIZHUANG, serplulimab, an innovative anti-PD-1 mAb independently developed by the company, in combination with chemotherapy as a first-line treatment for patients

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: